CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79.75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

US judge won't block Eli Lilly ads for weight-loss drugs, rules against Novo Nordisk

By Reuters News

By Jonathan Stempel

Oct 26 (Reuters) - A US judge on Monday rejected Novo Nordisk's NOVOb.CO request to block Eli Lilly LLY.N from continuing weight-loss drug advertisements that the Danish drugmaker considered false and misleading.

Novo Nordisk had requested a preliminary injunction to halt Eli Lilly's advertising while the case proceeded.

US District Judge Zahid Quraishi in Trenton, New Jersey rejected that request, calling Novo Nordisk's claim of irreparable harm "inadequate to warrant the extraordinary relief it seeks."

Weight-loss drugs have become major businesses for large pharmaceutical companies. The United States is one of only a handful of countries that allow direct-to-consumer advertising of prescription medicines.

Novo Nordisk sued Eli Lilly in July, saying ads for the obesity drug Zepbound and diabetes treatment Mounjaro compared higher doses of those products with lower doses of Novo Nordisk's Wegovy and Ozempic.

The ads claiming that Eli Lilly drugs were superior violated false advertising and unfair competition laws, justifying an injunction, Novo Nordisk said.

Eli Lilly has denied wrongdoing.

Novo Nordisk is working to regain market share in the United States for its injectable obesity drugs, a market projected to exceed $100 billion by the end of the decade.

Quraishi ruled following a hearing on August 27 and 28.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.